Explore the words cloud of the InflaPML project. It provides you a very rough idea of what is the project "InflaPML" about.
The following table provides information about the project.
Coordinator |
UNIVERSITA DEGLI STUDI DI FERRARA
Organization address contact info |
Coordinator Country | Italy [IT] |
Total cost | 1˙462˙500 € |
EC max contribution | 1˙462˙500 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2019-STG |
Funding Scheme | ERC-STG |
Starting year | 2020 |
Duration (year-month-day) | from 2020-03-01 to 2025-02-28 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITA DEGLI STUDI DI FERRARA | IT (FERRARA) | coordinator | 1˙462˙500.00 |
Local sterile inflammation arise in many pathologic states, including several diseases of the nervous system as brain stroke, neurodegenerative diseases and epilepsy. The persistent and de-regulated inflammatory response sustains these neurological pathologies worsening their prognosis. Different molecular players, as NLRP3 and P2X7 have been shown to contribute to the progression of these illnesses triggering the release of IL-1β and recruiting cellular components of the immune response at the neurodegeneration site. Consistently, brain penetrant P2X7 antagonists are clinically used to treat epilepsy and neurodegenerative diseases, while the pharmacological modulation of IL-1β is still unsuccessful. Unfortunately, the molecular mechanism underlying neuroinflammation and NLRP3 inflammasome assembly remains elusive. Here we propose that different neuroinflammatory diseases can be linked together in a common disease pathway, of which damaged function should be targeted for therapy. Specifically we propose a new mechanism acting on IL-1β regulation: we hypothesize the existence of a new activity of PML outside tumour environment, acting at the endoplasmic reticulum-mitochondria interfaces (MAMs) as modulator of NLRP3 inflammasome. On these bases, I propose a project in which PML activity at MAMs can be the key link of different neuroinflammatory diseases. Our goals are as follow: 1) to demonstrate that PML post-transcriptionally controls NLRP3 activity at the ER/MAMs compartments and thus IL-1β release via P2X7; 2) to prove that IL-1β release have a strong influence on neuronal environment and survival, and might represent a prognostic factor; 3) to develop new drugs targeting PML/NLRP3/P2X7 axis to overcome the unexpected failure of anti-IL-1 therapies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFLAPML" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INFLAPML" are provided by the European Opendata Portal: CORDIS opendata.
High-throughput single-cell phenotypic analysis of functional antibody repertoires
Read MoreWhy is the world green: testing top-down control of plant-herbivore food webs by experiments with birds, bats and ants
Read MoreMolecular mechanisms underlying selective neuronal death in motor neuron diseases
Read More